PURPOSE: The present work was aimed at the formulation and evaluation of freeze-dried kits of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-peptides for the preparation of (68)Ga-labelled peptides for PET imaging of neuroendocrine tumours. The (68)GaCl3 was obtained from the locally produced nanoceria-PAN, composite-sorbent-based (68)Ge/(68)Ga generator. PROCEDURES: Single vial kits of somatostatin analogues DOTA-[Tyr(3)]-octreotide (DOTA-TOC), DOTA-[NaI(3)]-octreotide (DOTA-NOC) and DOTA-Tyr(3)-Thre(8)-octreotide (DOTA-TATE) were formulated. Optimization of radiolabelling with (68)Ga from the in-house generator, characterization, long term evaluation of stability of kits and bioevaluation studies in animals was carried out. RESULTS: DOTA-TOC, DOTA-NOC and DOTA-TATE kits could be successfully formulated. Consistently high radiochemical yields (>95 %) were obtained on radiolabelling with (68)Ga. The radiolabelled peptides exhibited excellent in vitro stability. Biodistribution studies in normal non-tumour bearing Swiss mice revealed fast clearance of activity via renal route as reported for the respective peptides. CONCLUSION: Availability of ready to use DOTA-peptide kits in conjunction with (68)Ge/(68)Ga generators would pave way for the establishment of (68)Ga radiopharmacy, a long-felt need of the nuclear medicine community.
PURPOSE: The present work was aimed at the formulation and evaluation of freeze-dried kits of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-peptides for the preparation of (68)Ga-labelled peptides for PET imaging of neuroendocrine tumours. The (68)GaCl3 was obtained from the locally produced nanoceria-PAN, composite-sorbent-based (68)Ge/(68)Ga generator. PROCEDURES: Single vial kits of somatostatin analogues DOTA-[Tyr(3)]-octreotide (DOTA-TOC), DOTA-[NaI(3)]-octreotide (DOTA-NOC) and DOTA-Tyr(3)-Thre(8)-octreotide (DOTA-TATE) were formulated. Optimization of radiolabelling with (68)Ga from the in-house generator, characterization, long term evaluation of stability of kits and bioevaluation studies in animals was carried out. RESULTS:DOTA-TOC, DOTA-NOC and DOTA-TATE kits could be successfully formulated. Consistently high radiochemical yields (>95 %) were obtained on radiolabelling with (68)Ga. The radiolabelled peptides exhibited excellent in vitro stability. Biodistribution studies in normal non-tumour bearing Swiss mice revealed fast clearance of activity via renal route as reported for the respective peptides. CONCLUSION: Availability of ready to use DOTA-peptide kits in conjunction with (68)Ge/(68)Ga generators would pave way for the establishment of (68)Ga radiopharmacy, a long-felt need of the nuclear medicine community.
Authors: Wouter A P Breeman; Marion de Jong; Erik de Blois; Bert F Bernard; Mark Konijnenberg; Eric P Krenning Journal: Eur J Nucl Med Mol Imaging Date: 2005-01-18 Impact factor: 9.236
Authors: H J Wester; M Schottelius; K Scheidhauer; G Meisetschläger; M Herz; F C Rau; J C Reubi; M Schwaiger Journal: Eur J Nucl Med Mol Imaging Date: 2002-11-05 Impact factor: 9.236
Authors: Wouter A P Breeman; Erik de Blois; Ho Sze Chan; Mark Konijnenberg; Dik J Kwekkeboom; Eric P Krenning Journal: Semin Nucl Med Date: 2011-07 Impact factor: 4.446
Authors: Erik de Blois; Ho Sze Chan; Clive Naidoo; Deidre Prince; Eric P Krenning; Wouter A P Breeman Journal: Appl Radiat Isot Date: 2010-11-23 Impact factor: 1.513
Authors: Marion de Jong; Wout A P Breeman; Dik J Kwekkeboom; Roelf Valkema; Eric P Krenning Journal: Acc Chem Res Date: 2009-07-21 Impact factor: 22.384
Authors: Thomas Ebenhan; Isabel Schoeman; Daniel D Rossouw; Anne Grobler; Biljana Marjanovic-Painter; Judith Wagener; Hendrik G Kruger; Mike M Sathekge; Jan Rijn Zeevaart Journal: Mol Imaging Biol Date: 2017-06 Impact factor: 3.488